Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems

Definitions

• the present invention relates to organic compounds useful for therapy or prophylaxis in a mammal, and in particular to autotaxin (ATX) inhibitors which are inhibitors of lysophosphatidic acid (LPA) production and thus modulators of LPA levels and associated signaling, for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and chronic organ transplant rejection.
• ATX autotaxin
• LPA lysophosphatidic acid
• the present invention provides novel compounds of formula (I)
• ATX Autotaxin
• LPC lysophosphatidyl choline
• LPA bioactive signaling molecule lysophosphatidic acid
• LPA can elicit a wide range of cellular responses; including smooth muscle cell contraction, platelet activation, cell proliferation, chemotaxis and others.
• LPA mediates its effects via signaling to several G protein coupled receptors (GPCRs); the first members were originally denoted Edg (endothelial cell differentiation gene) receptors or ventricular zone gene-1(vzg-1) but are now called LPA receptors.
• GPCRs G protein coupled receptors
• Edg endothelial cell differentiation gene
• ventricular zone gene-1(vzg-1) ventricular zone gene-1(vzg-1) but are now called LPA receptors.
• the prototypic group now consists of LPA1/Edg-2NZG-1, LPA2/Edg-4, and LPA3/Edg-7.
• the ATX-LPA signaling axis is involved in a large range of physiological and pathophysiological functions, including, for example, nervous system function, vascular development, cardiovascular physiology, reproduction, immune system function, chronic inflammation, tumor metastasis and progression, organ fibrosis as well as obesity and/or other metabolic diseases such as diabetes mellitus. Therefore, increased activity of ATX and/or increased levels of LPA, altered LPA receptor expression and altered responses to LPA may contribute to the initiation, progression and/or outcome of a number of different pathophysiological conditions related to the ATX/LPA axis.
• the compounds of formula (I) or their pharmaceutically acceptable salts and esters can be used for the treatment or prophylaxis of diseases, disorders or conditions that are associated with the activity of autotaxin and/or the biological activity of lysophosphatidic acid (LPA).
• LPA lysophosphatidic acid
• the compounds of formula (I) or their pharmaceutically acceptable salts and esters herein inhibit autotaxin activity and therefore inhibit LPA production and modulate LPA levels and associated signaling.
• Autotaxin inhibitors described herein are useful as agents for the treatment or prevention of diseases or conditions in which ATX activity and/or LPA signaling participates, is involved in the etiology or pathology of the disease, or is otherwise associated with at least one symptom of the disease.
• the ATX-LPA axis has been implicated for example in angiogenesis, chronic inflammation, autoimmune diseases, fibrotic diseases, cancer and tumor metastasis and progression, ocular conditions, metabolic conditions such as obesity and/or diabetes mellitus, conditions such as cholestatic or other forms of chronic pruritus as well as acute and chronic organ transplant rejection.
• Objects of the present invention are the compounds of formula (I) and their aforementioned salts and esters and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically acceptable salts or esters, the use of the said compounds, salts or esters for the treatment or prophylaxis of disorders or conditions that are associated with the activity of ATX and/or the biological activity of lysophosphatidic acid (LPA), particularly in the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and—chronic organ transplant rejection, and the use of the said compounds, salts or esters for the production of medicaments for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and
• alkenyl denotes a monovalent linear or branched hydrocarbon group of 2 to 7 carbon atoms with at least one double bond. In particular embodiments, alkenyl has 2 to 4 carbon atoms with at least one double bond. Examples of alkenyl include ethenyl, propenyl, prop-2-enyl, isopropenyl, n-butenyl and iso-butenyl. Particular alkenyl group is ethenyl.
• alkoxy denotes a group of the formula —O—R′, wherein R′ is an alkyl group.
• alkoxy group include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy.
• Particular alkoxy group include isopropoxy.
• alkoxyalkoxy denotes an alkoxy group wherein at least one of the hydrogen atoms of the alkoxy group has been replaced by another alkoxy group.
• alkoxyalkoxy group examples include methoxymethoxy, ethoxymethoxy, methoxyethoxy, ethoxyethoxy, methoxypropoxy and ethoxypropoxy.
• Particular alkoxyalkoxy groups include methoxymethoxy and methoxyethoxy.
• alkoxyalkoxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by an alkoxyalkoxy group.
• alkoxyalkoxyalkyl group include methoxymethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, ethoxyethoxymethyl, methoxypropoxymethyl, ethoxypropoxymethyl, methoxymethoxyethyl, ethoxymethoxyethyl, methoxyethoxyethyl, ethoxyethoxyethyl, methoxypropoxyethyl and ethoxypropoxyethyl.
• alkoxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by an alkoxy group.
• alkoxyalkyl groups include methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, methoxypropyl, ethoxypropyl and isopropoxymethyl.
• Particular alkoxyalkyl group include include methoxymethyl, methoxyethyl and isopropoxymethyl.
• alkoxycarbonyl denotes a group of the formula —C(O)—R′, wherein R′ is an alkoxy group.
• alkoxycarbonyl groups include groups of the formula —C(O)—R′, wherein R′ is methoxy or ethoxy.
• Particular alkoxycarbonyl group include groups of the formula —C(O)—R′, wherein R′ is methoxy.
• alkoxyhaloalkyl denotes a haloalkyl group wherein at least one of the hydrogen atoms of the haloalkyl group has been replaced by an alkoxy group.
• alkoxyalkyl groups include methoxytrifluoroethyl, ethoxytrifluoroethyl, methoxytrifluoropropyl and ethoxytrifluoropropyl.
• alkyl denotes a monovalent linear or branched saturated hydrocarbon group of 1 to 12 carbon atoms. In particular embodiments, alkyl has 1 to 7 carbon atoms, and in more particular embodiments 1 to 4 carbon atoms. Examples of alkyl include methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl and sec-butyl, pentyl. Particular alkyl groups include methyl, ethyl, propyl and isopropyl. More particular alkyl group is methyl.
• alkylcarbonyl denotes a group of the formula —C(O)—R′, wherein R′ is an alkyl group.
• alkylcarbonyl groups include groups of the formula —C(O)—R′, wherein R′ is methyl or ethyl.
• Particular alkylcarbonyl groups include groups of the formula —C(O)—R′, wherein R′ is methyl.
• alkylcarbonylamino denotes a group of the formula —NH—C(O)—R′, wherein R′ is an alkyl group.
• alkylcarbonylamino groups include groups of the formula —NH—C(O)—R′, wherein R′ is methyl or ethyl.
• Particular a alkylcarbonylamino groups include groups of the formula —NH—C(O)—R′, wherein R′ is methyl.
• alkylsulfanyl denotes a group of the formula —S—R′, wherein R′ is an alkyl group.
• alkylsulfanyl groups include groups of the formula —S—R′, wherein R′ is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl.
• Particular alkylsulfanyl groups include group of the formula —S—R′, wherein R′ is methyl.
• alkylsulfinyl denotes a group of the formula —S(O)—R′, wherein R′ is an alkyl group.
• alkylsulfinyl groups include groups of the formula —S(O)—R′, wherein R′ is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl.
• Particular alkylsulfinyl groups include group of the formula —S(O)—R′, wherein R′ is methyl.
• alkylsulfonyl denotes a group of the formula —S(O) 2 —R′, wherein R′ is an alkyl group.
• alkylsulfonyl groups include groups of the formula —S(O) 2 —R′, wherein R′ is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl.
• Particular alkylsulfonyl groups include group of the formula —S(O) 2 —R′, wherein R′ is methyl.
• alkylsulfonylamino denotes a group of the formula —NH—S(O) 2 —R′, wherein R′ is an alkyl group.
• alkylsulfonylamino groups include groups of the formula —NH—S(O) 2 —R′, wherein R′ is methyl or ethyl.
• Particular a alkylsulfonylamino groups include groups of the formula —NH—S(O) 2 —R′, wherein R′ is methyl.
• amino denotes a —NH 2 group.
• aminoalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by an aminogroup.
• aminoalkyl include aminomethyl, aminoethyl, amino-1-methyl-ethyl, aminopropyl, aminomethylpropyl and aminopropyl. Particular examples are aminomethyl and haminoethyl.
• aminosulfonyl denotes a —S(O) 2 —NH 2 group.
• carbonyl denotes a —C(O)— group.
• cyano denotes a —C ⁇ N group.
• cycloalkoxy denotes a group of the formula —O—R′, wherein R′ is a cycloalkyl group.
• examples of cycloalkoxy group include cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy and cyclooctyloxy.
• Particular cycloalkoxy group is cyclopropoxy.
• cycloalkoxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a cycloalkoxy group.
• cycloalkoxyalkyl groups include cyclopropoxymethyl, cyclopropoxyethyl, cyclobutoxymethyl, cyclobutoxyethyl, cyclopentyloxymethyl, cyclopentyloxyethyl, cyclohexyloxymethyl, cyclohexyloxyethyl, cycloheptyloxymethyl, cycloheptyloxyethyl, cyclooctyloxymethyl and cyclooctyloxyethyl.
• cycloalkyl denotes a monovalent saturated monocyclic or bicyclic hydrocarbon group of 3 to 10 ring carbon atoms.
• cycloalkyl denotes a monovalent saturated monocyclic hydrocarbon group of 3 to 8 ring carbon atoms.
• Bicyclic means a ring system consisting of two saturated carbocycles having two carbon atoms in common.
• monocyclic cycloalkyl are cyclopropyl, cyclobutanyl, cyclopentyl, cyclohexyl or cycloheptyl.
• bicyclic cycloalkyl are bicyclo[2.2.1]heptanyl or bicyclo[2.2.2]octanyl.
• Particular monocyclic cycloalkyl groups are cyclopropyl, cyclobutanyl, cyclopentyl and cyclohexyl. More particular monocyclic cycloalkyl group is cyclopropyl.
• cycloalkylalkoxy denotes an alkoxy group wherein at least one of the hydrogen atoms of the alkoxy group is replaced by a cycloalkyl group.
• examples of cycloalkylalkoxy include cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, cycloheptylmethoxy and cyclooctylmethoxy.
• cycloalkylalkoxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group is replaced by a cycloalkylalkoxy group.
• cycloalkylalkoxyalkyl include cyclopropylmethoxymethyl, cyclopropylmethoxyethyl, cyclobutylmethoxymethyl, cyclobutylmethoxyethyl, cyclopentylmethoxyethyl, cyclopentylmethoxyethyl, cyclohexylmethoxymethyl, cyclohexylmethoxyethyl, cycloheptylmethoxymethyl, cycloheptylmethoxyethyl, cyclooctylmethoxymethyl and cyclooctylmethoxyethyl.
• cycloalkylalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group is replaced by a cycloalkyl group.
• examples of cycloalkylalkyl include cyclopropylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylpropyl, 2-cyclopropylbutyl, cyclopentylbutyl, cyclohexylmethyl, cyclohexylethyl, bicyclo[4.1.0]heptanylmethyl, bicyclo[4.1.0]heptanylethyl, bicyclo[2.2.2]octanylmethyl, bicyclo[2.2.2]octanylethyl, adamentanylmethyl and adamantanylethyl.
• cycloalkylalkyl are cyclohexylmethyl, cyclohexylethyl, bicyclo[4.1.0]heptanylmethyl, bicyclo[4.1.0]heptanylethyl, bicyclo[2.2.2]octanylmethyl, bicyclo[2.2.2]octanylethyl, adamentanylmethyl and adamantanylethyl.
• cycloalkylalkyl are cyclohexylmethyl, cyclohexylethyl, bicyclo[4.1.0]heptanylmethyl, bicyclo[2.2.2]octanylmethyl, adamentanylmethyl and adamantanylethyl.
• cycloalkylcarbonyl of the formula —C(O)—R′, wherein R′ is a cycloalkyl group.
• cycloalkylcarbonyl groups include groups of the formula —C(O)—R′, wherein R′ is cyclopropyl.
• cycloalkylsulfanyl denotes a group of the formula —S—R′, wherein R′ is a cycloalkyl group.
• examples of cycloalkylsulfanyl groups include groups of the formula —S—R′, wherein R′ is cyclopropyl.
• cycloalkylsulfinyl denotes a group of the formula —S(O)—R′, wherein R′ is a cycloalkyl group.
• examples of cycloalkylsulfinyl groups include groups of the formula —S(O)—R′, wherein R′ is cyclopropyl.
• cycloalkylsulfonyl denotes a group of the formula —S(O) 2 —R′, wherein R′ is a cycloalkyl group.
• examples of cycloalkylsulfonyl groups include groups of the formula —S(O) 2 —R′, wherein R′ is cyclopropyl.
• haloalkoxy denotes an alkoxy group wherein at least one of the hydrogen atoms of the alkoxy group has been replaced by the same or different halogen atoms.
• perhaloalkoxy denotes an alkoxy group where all hydrogen atoms of the alkoxy group have been replaced by the same or different halogen atoms.
• haloalkoxy include fluoromethoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy, trifluoromethylethoxy, trifluorodimethylethoxy and pentafluoroethoxy.
• Particular haloalkoxy group is trifluoromethoxy.
• haloalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by the same or different halogen atoms.
• perhaloalkyl denotes an alkyl group where all hydrogen atoms of the alkyl group have been replaced by the same or different halogen atoms. Examples of haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, trifluoromethylethyl and pentafluoroethyl. Particular haloalkyl group is trifluoromethyl.
• haloalkylsulfanyl denotes a group of the formula —S—R′, wherein R′ is a haloalkyl group.
• haloalkylsulfanyl groups include groups of the formula —S—R′, wherein R′ is trifluoromethyl.
• haloalkylsulfinyl denotes a group of the formula —S(O)—R′, wherein R′ is a haloalkyl group.
• haloalkylsulfinyl groups include groups of the formula —S(O)—R′, wherein R′ is trifluoromethyl.
• haloalkylsulfonyl denotes a group of the formula —S(O) 2 —R′, wherein R′ is a haloalkyl group.
• haloalkylsulfonyl groups include groups of the formula —S(O) 2 —R′, wherein R′ is trifluoromethyl.
• halogen and “halo” are used interchangeably herein and denote fluoro, chloro, bromo, or iodo. Particular halogens are chloro and fluoro.
• hydroxy denotes a —OH group.
• hydroxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a hydroxy group.
• examples of hydroxyalkyl include hydroxymethyl, hydroxyethyl, hydroxy-1-methyl-ethyl, hydroxypropyl, hydroxymethylpropyl and dihydroxypropyl. Particular examples are hydroxymethyl and hydroxyethyl.
• hydroxyhaloalkyl denotes a haloalkyl group wherein at least one of the hydrogen atoms of the haloalkyl group has been replaced by an hydroxy group.
• exemplary hydroxyhaloalkyl groups include hydroxytrifluoroethyl and hydroxytrifluoropropyl.
• Particular hydroxyhaloalkyl groups include hydroxytrifluoroethyl.
• naphthylalkenyl denotes an alkenyl group wherein at least one of the hydrogen atoms of the alkenyl group has been replaced a naphthynaphthyl. Particular naphthylalkenyl group is naphytylethenyl.
• naphthylalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced a naphthyl.
• Particular naphthylalkyl groups are naphthylmethyl, naphthylethyl and naphthylpropyl.
• naphthyloxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a naphthyloxy group.
• exemplary naphthyloxyalkyl groups include naphthyloxymethyl, naphthyloxyethyl and naphthyloxypropyl.
• phenoxy denotes a group of the formula —O—R′, wherein R′ is a phenyl.
• phenoxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a phenoxy group.
• exemplary phenoxyalkyl groups include phenoxymethyl, phenoxyethyl and phenoxypropyl.
• Particular alkoxyalkyl group is phenoxymethyl.
• phenylalkenyl denotes an alkenyl group wherein at least one of the hydrogen atoms of the alkenyl group has been replaced a phenyl.
• Particular phenylalkenyl group is phenylethenyl.
• phenylalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced a phenyl.
• Particular phenylalkyl groups are benzyl, phenethyl and phenylpropyl. More particular phenylalkyl groups are benzyl and phenethyl. Further particular phenylalkyl group is benzyl.
• phenylalkynyl denotes an alkynyl group wherein at least one of the hydrogen atoms of the alkynyl group has been replaced a phenyl. Particular phenylalkynyl group is phenylethynyl.
• phenylcyloalkyl denotes a cycloalkyl group wherein at least one of the hydrogen atoms of the cycloalkyl group has been replaced a phenyl.
• Particular phenylcycloalkyl group is phenylcyclopropyl.
• pyridinylalkenyl denotes an alkenyl group wherein at least one of the hydrogen atoms of the alkenyl group has been replaced a pyridinyl.
• Particular pyridinylalkenyl group is pyridinylethenyl.
• pyridinylalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced a pyridinyl.
• Particular pyridinylalkyl groups are pyridinylmethyl, pyridinylethyl and pyridinylpropyl. More particular pyridinylalkyl group is pyridinylethyl.
• pyridinylalkynyl denotes an alkynyl group wherein at least one of the hydrogen atoms of the alkynyl group has been replaced a pyridinyl.
• Particular pyridinylalkynyl group is pyridinylethynyl.
• thiophenylalkenyl denotes an alkenyl group wherein at least one of the hydrogen atoms of the alkenyl group has been replaced a thiophenyl. Particular thiophenylalkenyl group is thiophenylethenyl.
• thiophenylalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced a thiophenyl.
• Particular thiophenylalkyl groups are thiophenylmethyl, thiophenylethyl and thiophenylpropyl. More particular thiophenylalkyl group is thiophenylmethyl.
• thiophenylalkynyl denotes an alkynyl group wherein at least one of the hydrogen atoms of the alkynyl group has been replaced a thiophenyl. Particular thiophenylalkynyl group is thiophenylethynyl.
• salts refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable.
• the salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, in particular hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein and the like.
• salts may be prepared by addition of an inorganic base or an organic base to the free acid.
• Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like.
• Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyimine resins and the like.
• Particular pharmaceutically acceptable salts of compounds of formula (I) are the sodium and potassium salts.
• “Pharmaceutically acceptable esters” means that compounds of general formula (I) may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compounds in vivo. Examples of such compounds include physiologically acceptable and metabolically labile ester derivatives, such as methoxymethyl esters, methylthiomethyl esters and pivaloyloxymethyl esters. Additionally, any physiologically acceptable equivalents of the compounds of general formula (I), similar to the metabolically labile esters, which are capable of producing the parent compounds of general formula (I) in vivo, are within the scope of this invention.
• protecting group denotes a group which selectively blocks a reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry.
• Protecting groups can be removed at the appropriate point.
• Exemplary protecting groups are amino-protecting groups, carboxy-protecting groups or hydroxy-protecting groups.
• Particular protecting groups are the tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), fluorenylmethoxycarbonyl (Fmoc) and benzyl (Bn) groups.
• Further particular protecting groups are the tert-butoxycarbonyl (Boc) and the fluorenylmethoxycarbonyl (Fmoc) groups. More particular protecting group is the tert-butoxycarbonyl (Boc) group.
• uM means microMolar and is equivalent to the symbol ⁇ M.
• the abbreviation uL means microliter and is equivalent to the symbol ⁇ L.
• the abbreviation ug means microgram and is equivalent to the symbol ⁇ g.
• the compounds of formula (I) can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
• the asymmetric carbon atom can be of the “R” or “S” configuration.
• an embodiment of the present invention are compounds according to formula (I) as described herein and pharmaceutically acceptable salts or esters thereof, in particular compounds according to formula (I) as described herein and pharmaceutically acceptable salts thereof, more particularly compounds according to formula (I) as described herein.
• a further embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 1 is substituted phenyl, substituted phenylalkyl, substituted phenylalkenyl, substituted naphthyl, substituted indolyl, substituted quinolyl, or substituted isoquinolyl, wherein substituted phenyl, substituted phenylalkyl, substituted phenylalkenyl, substituted naphthyl, substituted indolyl, substituted quinolyl and substituted isoquinolyl are substituted with R 7 , R 8 and R 9 .
• a particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 1 is phenylalkyl substituted with R 7 , R 8 and R 9 .
• the present invention also relates to compounds according to formula (I) as described herein, wherein R 1 is substituted phenyl or substituted pyridinyl, wherein substituted phenyl and substituted pyridinyl are substituted with R 10 , R 11 and R 12 .
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 2 is phenyl substituted phenyl with R 10 , R 11 and R 12 .
• R 2 is 4-aminosulfonylphenyl, 3-fluoro-4-aminosulfonylphenyl, 3-aminosulfonylpyridin-6-yl or 2-aminosulfonylpyridin-5-yl.
• Another embodiment of the present invention are compounds according to formula (I) as described herein, wherein Y is —OC(O)— or —C(O)—.
• a more particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein A is —N—.
• an embodiment of the present invention are compounds according to formula (I) as described herein, wherein W is —C(O)— or —S(O) 2 —.
• Another embodiment of the present invention are compounds according to formula (I) as described herein, wherein W is —C(O)—.
• R 7 , R 8 and R 9 are independently selected from H, alkoxy, haloalkoxy, halogen, alkylsulfonyl and phenyl substituted with one halogen, and wherein at least one of R 7 , R 8 and R 9 is not H.
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 7 is alkoxy, haloalkoxy, halogen or phenyl substituted with one halogen.
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 7 is haloalkoxy or halogen.
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 8 is H, halogen or alkylsulfonyl.
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 8 is H or halogen.
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 9 is H.
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 10 is aminosulfonyl.
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 11 and R 12 are independently selected from H, alkyl and halogen.
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 11 and R 12 are independently selected from H and halogen.
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein m and n are 1.
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein m, n, p and q are 1.
• a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 2 is 4-aminosulfonylphenyl and of formula (Ia).
• the preparation of compounds of formula (I) of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following general schemes. The skills required for carrying out the reactions and purifications of the resulting products are known to those persons skilled in the art. In case a mixture of enantiomers or diastereoisomers is produced during a reaction, these enantiomers or diastereoisomers can be separated by methods described herein or known to the man skilled in the art such as e.g. (chiral) chromatography or crystallization. The substituents and indices used in the following description of the processes have the significance given herein.
• amine 1 is reacted with a suitable chloroformate ester of formula R 1 —O—C(O)—Cl (2), or with an imidazole-1-carboxylate ester of formula (3), leading to a compound of formula (I) wherein Y is —OC(O)—.
• the reaction is performed in a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence of a base, e.g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
• a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof
• a base e.g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
• Chloroformate esters 2 are commercially available or can be synthesised from the corresponding alcohol of formula R 1 —OH, by reaction with phosgene or a phosgene equivalent (e.g., diphosgene, triphosgene), as described in the literature.
• phosgene or a phosgene equivalent e.g., diphosgene, triphosgene
• Imidazole-1-carboxylate esters 3 are synthesised from the corresponding alcohols of formula R 1 —OH, by reaction with 1,1′-carbonyldiimidazole. The reaction is performed at room temperature, in a solvent such as dichloromethane, tetrahydrofuran or acetonitrile. The imidazole-1-carboxylate esters 3 are typically not isolated but directly reacted with amines 1 as described above.
• Alcohols of formula R 1 —OH are commercially available or can be produced by methods described herein or known in the art.
• amine 1 is reacted with a suitable N-(chlorocarbonyl)amine of formula R 1 —N(R 5 )—C(O)—Cl (4), or, in the case where R 5 is H, with an isocyanate of formula R 1 —NCO (5), leading to compounds of formula (I) wherein Y is —NR 5 C(O)—.
• N-(Chlorocarbonyl)amines (4) are synthesised from the corresponding amines of formula R 1 —N(R 5 )H by reaction with phosgene or a phosgene equivalent, as described in the literature.
• Isocyanates 5 are commercially available or can be prepared from the corresponding amines of formula R 1 —NH 2 , by reaction with phosgene or a phosgene equivalent (e.g., diphosgene, triphosgene, 1,1′-carbonyldiimidazole) using conditions described in the literature.
• phosgene or a phosgene equivalent e.g., diphosgene, triphosgene, 1,1′-carbonyldiimidazole
• amine 1 is reacted with a suitable carboxylic acid of formula R 1 —COOH (6) leading to a compound of formula (I), wherein Y is —C(O)—.
• the reaction is performed in the presence of a coupling agent such as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate or bromo-tris-pyrrolidino-phosphonium hexafluorophosphate, in aprotic solvents such as dichloromethan
• Amine 1 can also be reacted with suitable acylating reagents such as acyl chlorides of formula R 1 —COCl (7) to lead to compounds of formula (I) wherein Y is —C(O)—.
• suitable acylating reagents such as acyl chlorides of formula R 1 —COCl (7) to lead to compounds of formula (I) wherein Y is —C(O)—.
• the reaction is performed in a solvent such as dichloromethane, tetrahydrofuran, or N,N-dimethylformamide, in the presence of a base such as triethylamine or 4-methylmorpholine, at temperatures between 0° C. and 80° C.
• Carboxylic acids (6) and acyl halides (7) are commercially available or can be prepared as described herein or in the literature.
• amine 1 is reacted with a suitable sulfonyl chloride of formula R 1 —SO 2 Cl (8), leading to compounds of formula (I) wherein Y is —S(O 2 )—.
• a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence of a base, e.g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
• Sulfonyl chlorides (8) are commercially available or can be synthesised as described herein or in the literature.
• amine 1 is reacted with a suitable chloro-oxadiazole reagent of general formula 9, or with oxadiazolone reagent 10, leading to a compound of formula (I), wherein Y is
• reaction is performed in the presence of a base, e.g., potassium carbonate, triethylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene, in a solvent such as toluene, ethanol, N,N-dimethylformamide, or 1,4-dioxane at temperatures between 20° C. and 150° C.
• a base e.g., potassium carbonate, triethylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene
• reaction is performed in the presence of a coupling agent, e.g. benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate and a base, e.g., diisopropylethylamine or 4-methylmorpholine, in a solvent such as N,N-dimethylformamide, at temperatures between 20° C. and 100° C. as described in the literature.
• a coupling agent e.g. benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate
• a base e.g., diisopropylethylamine or 4-methylmorpholine
• Oxadiazolones 10 are commercially available or can be produced as described in the literature.
• Chloro-oxadiazoles 9 are commercially available or can be produced from the corresponding oxadiazolones, by reaction with a suitable halogenating reagent, e.g. phosphorus oxychloride and/or phosphorus pentachloride, at temperatures between 60° C. and 120° C.
• a suitable halogenating reagent e.g. phosphorus oxychloride and/or phosphorus pentachloride
• amine 1 is reacted with a suitable halo-thiadiazole reagent of general formula 11 (X ⁇ Cl or Br), or with thiadiazolethione reagent 12, leading to compounds of (I) wherein Y is
• reaction is performed in the presence of a base, e.g. potassium carbonate, triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene, in a solvent such as toluene, ethanol, N,N-dimethylformamide or 1,4-dioxane, at temperatures between 20° C. and 150° C.
• a base e.g. potassium carbonate, triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene
• solvent such as toluene, ethanol, N,N-dimethylformamide or 1,4-dioxane
• Thiadiazolethiones 12 are commercially available or can be produced as described in the literature.
• Halo-thiadiazoles 11 are commercially available or can be produced as described in the literature.
• Amines of general formula 1 are synthesised from suitably protected precursors 13.
• Suitable protective groups are tert-butoxycarbonyl, benzyloxycarbonyl and substituted benzyloxycarbonyl such as 3,5-dichloro benzyloxycarbonyl.
• the deprotection of intermediates 13 can be performed using methods and reagents known in the art.
• the deprotection may be performed by hydrogenation at pressures between 1 bar and 100 bar, in the presence of a suitable catalyst such as palladium on activated charcoal, at temperatures between 20° C. and 150° C. in solvents such as methanol or ethanol.
• a suitable catalyst such as palladium on activated charcoal
• the deprotection may be performed in the presence of a suitable acid, e.g., hydrochloric acid or trifluoroacetic acid, in a solvent such as water, 2-propanol, dichloromethane, or 1,4-dioxane at temperatures between 0° C. and 30° C.
• a suitable acid e.g., hydrochloric acid or trifluoroacetic acid
• a solvent such as water, 2-propanol, dichloromethane, or 1,4-dioxane at temperatures between 0° C. and 30° C.
• PG is a suitable protective group, e.g., tert-butoxycarbonyl, benzyloxycarbonyl and substituted benzyloxycarbonyl such as 3,5-dichloro benzyloxycarbonyl.
• Intermediates 13A can be produced from amine precursors of general formula 14 by reaction with appropriate reagents, using methods known in the art.
• alkylating agents of general formula X—CR 3 R 4 —R 2 (15) where X is a leaving group such as Cl, Br, I, or OSO 2 CH 3 , leading to 13A, wherein W is —CR 3 R 4 —.
• This reaction is performed in a solvent such as tetrahydrofuran or N,N-dimethylformamide, in the presence of a base, e.g. triethylamine or potassium carbonate, at temperatures between 0° C. and 100° C.
• amine 14 is reacted with aldehydes or ketones of general formula R 4 —C(O)—R 2 (16) in a reductive amination reaction, leading to 13A.
• This reaction is performed in the presence of a suitable reducing agent, e.g., sodium borohydride or sodium triacetoxyborohydride, in a solvent such as methanol, acetic acid, tetrahydrofuran, 1,2-dichloroethane or mixtures thereof, at temperatures between 0° C. and 50° C.
• amine 14 is reacted with a suitable carboxylic acid of formula R 2 —COOH (17), leading to compounds of formula 13A, wherein W is —C(O)—.
• the reaction is performed in the presence of a coupling agent such as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, 0-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate or bromo-tris-pyrrolidino-phosphonium hexafluorophosphate, in aprotic solvents such as dichloromethane,
• amine 14 is reacted with a suitable sulfonyl chloride of formula R 2 —SO 2 Cl (18), leading to compounds of formula 13A, wherein W is —S(O 2 )—.
• a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence of a base, e.g. triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
• Amines 14, alkylating agents 15, aldehydes/ketones 16, carboxylic acids 17, sulfonyl chlorides 18, and amines 22 are commercially available or can be synthesised as described in the literature or in the experimental section.
• Intermediates 13 wherein A is C—H are represented by general formula 13B, wherein PG is a suitable protective group, e.g. tert-butoxycarbonyl, benzyloxycarbonyl and substituted benzyloxycarbonyl such as 3,5-dichloro benzyloxycarbonyl.
• PG is a suitable protective group, e.g. tert-butoxycarbonyl, benzyloxycarbonyl and substituted benzyloxycarbonyl such as 3,5-dichloro benzyloxycarbonyl.
• Compound 13B wherein W is —NR 6 —, is produced from ketone 19 by reaction with an amine of formula HN(R 6 )R 2 (20) in the presence of a suitable reducing agent, e.g. sodium borohydride or sodium triacetoxyborohydride, in a solvent such as methanol, acetic acid, tetrahydrofuran, 1,2-dichloroethane, or mixtures thereof, at temperatures between 0° C. and 50° C.
• a suitable reducing agent e.g. sodium borohydride or sodium triacetoxyborohydride
• Ketones 19 and amines 20 are commercially available or can be prepared as described in the literature.
• Compound 13B wherein W is —O— or —S—, is produced from alcohol 21 using methods and reagents known in the art.
• alcohol 24 is reacted at room temperature with phenol HO—R 2 or thiophenol HS—R 2 in the presence of triphenylphosphine and an dialkylazodicarboxylate, e.g. diisopropylazodicarboxylate or diethylazodicarboxylate, in a solvent such as toluene, dichloromethane, or tetrahydrofuran, leading to 13B, wherein W is —O— or —S—.
• dialkylazodicarboxylate e.g. diisopropylazodicarboxylate or diethylazodicarboxylate
• Compound 13B wherein W is —SO 2 —, is produced from compound 13B, wherein W is —S—, by oxidation with a suitable reagent, e.g., hydrogen peroxide or 3-chloroperbenzoic acid, in a solvent such as formic acid, acetic acid, or dichloromethane, at temperatures between 0° C. and 50° C.
• a suitable reagent e.g., hydrogen peroxide or 3-chloroperbenzoic acid
• a solvent such as formic acid, acetic acid, or dichloromethane
• Alcohols 21 are produced from ketones 19 using a suitable reducing agent, e.g., sodium borohydride, in a solvent such as methanol, at temperatures between 0° C. and 50° C.
• a suitable reducing agent e.g., sodium borohydride
• a solvent such as methanol
• Compounds of formula (I), wherein A is N can be produced from amine precursors of general formula 22 by reaction with appropriate reagents, using methods known in the art.
• an amine of formula 22 is reacted with alkylating agents of general formula X—CR 3 R 4 —R 2 (15) where X is a leaving group such as Cl, Br, I, or OSO 2 CH 3 , leading to compounds of formula (I), wherein A is N and W is —CR 3 R 4 —.
• This reaction is performed in a solvent such as tetrahydrofuran or N,N-dimethylformamide, in the presence of a base, e.g., triethylamine or potassium carbonate, at temperatures between 0° C. and 100° C.
• an amine of formula 22 is reacted with aldehydes or ketones of general formula R 4 —C(O)—R 2 (16) in a reductive amination reaction, leading to compounds of formula (I) wherein A is N, W is —CR 3 R 4 —, R 4 is hydrogen, alkyl or cycloalkyl, and R 3 is H.
• This reaction is performed in the presence of a suitable reducing agent, e.g. sodium borohydride or sodium triacetoxyborohydride, in a solvent such as methanol, acetic acid, tetrahydrofuran, 1,2-dichloroethane or mixtures thereof, at temperatures between 0° C. and 50° C.
• amine 22 is reacted with a suitable carboxylic acid of formula R 2 —COOH (17), leading to compounds of formula (I) wherein A is N and W is —C(O)—.
• the reaction is performed in the presence of a coupling agent such as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, 0-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate or bromo-tris-pyrrolidino-phosphonium hexafluorophosphate, in aprotic solvents such as dichlorome
• amine 22 is reacted with a suitable sulfonyl chloride of formula R 2 —SO 2 Cl (18), leading to (I) wherein A is N and W is —S(O 2 )—.
• a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence of a base, e.g. triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
• Amines 22 can be synthesised from their tert-butyl carbamate derivatives of formula 23 by carbamate deprotection.
• the deprotection may be performed in the presence of a suitable acid, e.g., hydrochloric acid or trifluoroacetic acid, in a solvent such as water, 2-propanol, dichloromethane, or 1,4-dioxane, at temperatures between 0° C. and 30° C.
• tert-Butyl carbamates 23 can be synthesised from amine precursors of formula 24 and appropriate reagents, using methods well known in the art.
• an amine of formula 24 is reacted with a suitable chloroformate ester of formula R 1 —O—C(O)—Cl (2), or with an imidazole-1-carboxylate ester of formula (3), leading to compounds of formula 23, wherein Y is —OC(O)—.
• the reaction is performed in a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence of a base, e.g. triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
• a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence of a base,
• an amine of formula 24 is reacted with a suitable N-(chlorocarbonyl)amine of formula R 1 —N(R 5 )—C(O)—Cl (4) leading to compounds of formula 23, wherein Y is —NR 5 C(O)—, or with an isocyanate of formula R 1 —NCO (5) leading to compounds of formula 23, wherein Y is —NR 5 C(O)— and R 5 is H.
• amine 24 is reacted with a suitable carboxylic acid of formula R 1 —COOH (6) leading to compounds of formula 23, wherein Y is —C(O)—.
• the reaction is performed in the presence of a coupling agent such as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate or bromo-tris-pyrrolidino-phosphonium hexafluorophosphate, in aprotic solvents such as dichloromethane, t
• Amine 24 can also be reacted with suitable acylating reagents, such as acyl chlorides of formula R 1 —COCl (7) to provide compounds of formula 23, wherein Y is —C(O)—.
• suitable acylating reagents such as acyl chlorides of formula R 1 —COCl (7) to provide compounds of formula 23, wherein Y is —C(O)—.
• the reaction is performed in a solvent such as dichloromethane, tetrahydrofuran, or N,N-dimethylformamide, in the presence of a base such as triethylamine or 4-methylmorpholine, at temperatures between 0° C. and 80° C.
• amine 24 is reacted with a suitable sulfonyl chloride, of formula R 1 —SO 2 Cl (8), leading to compounds of formula 23, wherein Y is —S(O 2 )—.
• a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence of a base, e.g. triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
• amine 24 is reacted with a suitable chloro-oxadiazole reagent of general formula 9, or with oxadiazolone reagent 10, leading to compounds of formula 23, wherein Y is
• reaction is performed in the presence of a base, e.g. potassium carbonate, triethylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene, in a solvent such as toluene, ethanol, N,N-dimethylformamide, or 1,4-dioxane, at temperatures between 20° C. and 150° C.
• a base e.g. potassium carbonate, triethylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene
• solvent such as toluene, ethanol, N,N-dimethylformamide, or 1,4-dioxane
• reaction is performed in the presence of a coupling agent, e.g., benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate, and a base, e.g. diisopropylethylamine or 4-methylmorpholine, in a solvent such as N,N-dimethylformamide, at temperatures between 20° C. and 100° C., as described in the literature).
• a coupling agent e.g., benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate
• a base e.g. diisopropylethylamine or 4-methylmorpholine
• amine 24 is reacted with a suitable halo-thiadiazole reagent of general formula 11 (X is Cl or Br), or with thiadiazolethione reagent 12, leading to compounds of formula 23, wherein Y is
• reaction is performed in the presence of a base, e.g. potassium carbonate, triethylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene, in a solvent such as toluene, ethanol, N,N-dimethylformamide, or 1,4-dioxane, at temperatures between 20° C. and 150° C.
• a base e.g. potassium carbonate, triethylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene
• solvent such as toluene, ethanol, N,N-dimethylformamide, or 1,4-dioxane
• reaction is performed in a solvent such as ethanol or N,N-dimethylformamide, at temperatures between 20° C. and 100° C., as described in the literature.
• amine 24 is acylated with a haloalkanoyl halide, e.g., bromoacetyl chloride, in the presence of a base, e.g. triethylamine, in a solvent such as dichloromethane or tetrahydrofuran, at temperatures between ⁇ 78° C. and +20° C., leading to the corresponding haloalkanamide intermediate, which in the presence of a base, e.g.
• a haloalkanoyl halide e.g., bromoacetyl chloride
• a base e.g. triethylamine
• a solvent such as dichloromethane or tetrahydrofuran
• potassium carbonate or caesium carbonate in a solvent such as N,N-dimethylformamide undergoes a nucleophilic substitution reaction with a substituted phenol, leading to compounds of formula 28, wherein Y is —C(O)— and R 1 is substituted phenoxyalkyl.
• Amines of formula 24 are commercially available or can be produced as described in the literature or in the experimental section.
• an embodiment of the present invention is a process to prepare a compound of formula (I) as defined above comprising the reaction of a compound of formula (II) in the presence of a compound of formula (III);
• a coupling agent such as O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate
• a solvent such as N,N-dimethylformamide
• a base such as 4-methylmorpholine and at a temperature comprised between ⁇ 78° C. and reflux, particularly between ⁇ 10° C. and room temperature.
• an object of the present invention is a compound according to formula (I) as described herein for use as a therapeutically active substance.
• an object of the present invention is a pharmaceutical composition
• a pharmaceutical composition comprising a compound according to formula (I) as described herein and a therapeutically inert carrier.
• An object of the invention is the use of a compound according to formula (I) as described herein for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and chronic organ transplant rejection.
• Renal conditions include, but are not limited to, acute kidney injury and chronic renal disease with and without proteinuria including end-stage renal disease (ESRD).
• ESRD end-stage renal disease
• this includes decreased creatinine clearance and decreased glomerular filtration rate, micro-albuminuria, albuminuria and proteinuria, glomerulosclerosis with expansion of reticulated mesangial matrix with or without significant hypercellularity (particularly diabetic nephropathy and amyloidosis), focal thrombosis of glomerular capillaries (particularly thrombotic microangiopathies), global fibrinoid necrosis, ischemic lesions, malignant nephrosclerosis (such as ischemic retraction, reduced renal blood flow and renal arteriopathy), swelling and proliferation of intracapillary (endothelial and mesangial) and/or extracapillary cells (crescents) like in glomerular nephritis entities, focal segmental glomerular sclerosis, IgA
• Liver conditions include, but are not limited to, liver cirrhosis, hepatic congestion, cholestatic liver disease including pruritus, nonalcoholic steatohepatitis and acute and chronic liver transplant rejection.
• Inflammatory conditions include, but are not limited to, arthritis, osteoarthritis, multiple sclerosis, systemic lupus erythematodes, inflammatory bowel disease, abnormal evacuation disorder and the like as well as inflammatory airways diseases such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) or chronic asthma bronchiale.
• IPF idiopathic pulmonary fibrosis
• COPD chronic obstructive pulmonary disease
• chronic asthma bronchiale chronic asthma bronchiale.
• Further conditions of the respiratory system include, but are not limited to, other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, systemic diseases and vasculitides, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, Langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease), radiation induced fibrosis, silicosis, asbestos induced pulmonary fibrosis or acute respiratory distress syndrome (ARDS).
• iatrogenic drug-induced fibrosis etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, systemic diseases and vasculitides, granulomatous diseases (s
• Conditions of the nervous system include, but are not limited to, neuropathic pain, schizophrenia, neuro-inflammation (e.g. astrogliosis), peripheral and/or autonomic (diabetic) neuropathies and the like.
• Vascular conditions include, but are not limited to, atherosclerosis, thrombotic vascular disease as well as thrombotic microangiopathies, proliferative arteriopathy (such as swollen myointimal cells surrounded by mucinous extracellular matrix and nodular thickening), atherosclerosis, decreased vascular compliance (such as stiffness, reduced ventricular compliance and reduced vascular compliance), endothelial dysfunction and the like.
• Cardiovascular conditions include, but are not limited to, acute coronary syndrome, coronary heart disease, myocardial infarction, arterial and pulmonary hypertension, cardiac arrhythmia such as atrial fibrillation, stroke and other vascular damage.
• Fibrotic diseases include, but are not limited to myocardial and vascular fibrosis, renal fibrosis, liver fibrosis, pulmonary fibrosis, skin fibrosis, scleroderma and encapsulating peritonitis.
• the compounds of formula (I) or their pharmaceutically acceptable salts and esters can be used for the treatment or prophylaxis of organ or skin fibrosis.
• the fibrotic disease is renal tubulo-interstitial fibrosis or glomerulosclerosis.
• the fibrotic disease is non-alcoholic liver steatosis, liver fibrosis or liver cirrhosis.
• the fibrotic disease is idiopathic pulmonary fibrosis.
• Cancer and cancer metastasis include, but are not limited to, breast cancer, ovarian cancer, lung cancer, prostate cancer, mesothelioma, glioma, hepatic carcinoma, gastrointestinal cancers and progression and metastatic aggressiveness thereof.
• Ocular conditions include, but are not limited to, proliferative and non-proliferative (diabetic) retinopathy, dry and wet age-related macular degeneration (AMD), macular edema, central arterial/venous occlusion, traumatic injury, glaucoma and the like.
• proliferative and non-proliferative (diabetic) retinopathy dry and wet age-related macular degeneration (AMD), macular edema, central arterial/venous occlusion, traumatic injury, glaucoma and the like.
• AMD age-related macular degeneration
• Metabolic conditions include, but are not limited to, obesity and diabetes.
• the compounds of formula (I) or their pharmaceutically acceptable salts and esters can be used for the treatment or prophylaxis of cholestatic or non-cholestatic chronic pruritus.
• the present invention also relates to the use of a compound according to formula (I) as described herein for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.
• the present invention also relates to the use of a compound according to formula (I) as described herein for the treatment or prophylaxis of renal conditions, liver conditions and fibrotic diseases.
• a particular embodiment of the present invention is a compound according to formula (I) as described herein for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.
• a particular embodiment of the present invention is a compound according to formula (I) as described herein for the treatment or prophylaxis of renal conditions, liver conditions and fibrotic diseases.
• the present invention also relates to the use of a compound according to formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.
• the present invention also relates to the use of a compound according to formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of renal conditions, liver conditions and fibrotic diseases.
• an object of the invention is a method for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection, which method comprises administering an effective amount of a compound according to formula (I) as described herein.
• an object of the invention is a method for the treatment or prophylaxis of renal conditions, liver conditions and fibrotic diseases, which method comprises administering an effective amount of a compound according to formula (I) as described herein.
• the renal condition is selected from the group consisting of acute kidney injury, chronic kidney disease, diabetic nephropathy, acute kidney transplant rejection and chronic allograft nephropathy.
• the renal condition is acute kidney injury.
• the renal condition is chronic kidney disease.
• the renal condition is diabetic nephropathy.
• the renal condition is acute kidney transplant rejection.
• the renal condition is chronic allograft nephropathy.
• the liver condition is acute and chronic liver transplant rejection
• the inflammatory condition is arthritis.
• the condition of the nervous system is neuropathic pain.
• the fibrotic disease is encapsulating peritonitis
• the fibrotic disease is idiopathic pulmonary fibrosis.
• the fibrotic disease is non-alcoholic liver steatosis, liver fibrosis or liver cirrhosis.
• cDNA was prepared from commercial human hematopoietic cells total RNA and used as template in overlapping PCR to generate a full length human ENPP2 ORF with or without a 3′-6 ⁇ His tag. These full length inserts were cloned into the pcDNA3.1V5-His TOPO (Invitrogen) vector. The DNA sequences of several single clones were verified. The DNA from a correct full length clone was used to transfect Hek293 cells for verification of protein expression. The sequence of the encoded ENPP2 conforms to Swissprot entry Q13822, with or without the additional C-terminal 6 ⁇ His tag.
• Recombinant protein was produced by large-scale transient transfection in 20 L controlled stirred tank bioreactors (Sartorius). During cell growth and transfection, temperature, stirrer speed, pH and dissolved oxygen concentration were maintained at 37° C., 120 rpm, 7.1 and 30% DO, respectively.
• FreeStyle 293-F cells (Invitrogen) were cultivated in suspension in FreeStyle 293 medium (Invitrogen) and transfected at ca. 1-1.5 ⁇ 10E6 cells/mL with above plasmid DNAs using X-tremeGENE Ro-1539 (commercial product, Roche Diagnostics) as complexing agent.
• the cleared supernatant was then applied to a HisTrap column (GE Healthcare) previously equilibrated in 50 mM Na 2 HPO 4 pH 7.0, 0.5 M NaCl, 10% glycerol, 0.3% CHAPS, 0.02% NaN 3 .
• the column was washed stepwise with the same buffer containing 20 mM, 40 mM and 50 mM imidazole, respectively.
• the protein was subsequently eluted using a linear gradient to 0.5 M imidazole in 15 column volumes.
• ATX containing fractions were pooled and concentrated using an Amicon cell equipped with a 30 kDa PES filter membrane.
• the protein was further purified by size exclusion chromatography on Superdex S-200 prep grade (XK 26/100) (GE Healthcare) in 20 mM BICINE pH 8.5, 0.15 M NaCl, 10% glycerol, 0.3% CHAPS, 0.02% NaN 3 . Final yield of protein after purification was 5-10 mg ATX per liter of culture supernatant. The protein was stored at ⁇ 80° C.
• ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate).
• MR121 substrate a specifically labeled substrate analogue
• BOC and TBS protected 6-amino-hexanoic acid (R)-3-( ⁇ 2-[3-(2- ⁇ 2-[2-(2-amino-ethoxy)-ethoxy]-ethoxy ⁇ -ethoxy)-propionylamino]-ethoxy ⁇ -hydroxy-phosphoryloxy)-2-hydroxy-propyl ester (Ferguson et al., Org Lett 2006, 8 (10), 2023) was labeled with MR121 fluorophore (CAS 185308-24-1, 1-(3-carboxypropyl)-11-ethyl-1,2,3,4,8,9,10,11-octahydro-dipyrido[3,2-b:2′,3′-i]phenoxazin-13-ium) on the free amine of the ethanolamine
• Assay buffer 50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.01% Triton-X-100, pH 8.0;
• ATX solution ATX (human His-tagged) stock solution (1.08 mg/mL in 20 mM bicine, pH 8.5, 0.15 M NaCl, 10% glycerol, 0.3% CHAPS, 0.02% NaN 3 ), diluted to 1.4-2.5 ⁇ final concentration in assay buffer;
• MR121 substrate solution MR121 substrate stock solution (800 ⁇ M MR121 substrate in DMSO), diluted to 2-5 ⁇ final concentration in assay buffer.
• Test compounds (10 mM stock in DMSO, 8 ⁇ L) were obtained in 384 well sample plates (Corning Costar #3655) and diluted with 8 ⁇ L DMSO. Row-wise serial dilutions were made by transferring 8 ⁇ L cpd solution to the next row up to row 0. The compound and control solutions were mixed five times and 2 ⁇ L were transferred to 384 well assay plates (Corning Costar #3702). Then, 15 ⁇ L of 41.7 nM ATX solution was added (30 nM final concentration), mixed five times and then incubated for 15 minutes at 30° C. 10 ⁇ L of MR121 substrate solution was added (1 ⁇ M final concentration), mixed 30 times and then incubated for 15 minutes at 30° C.
• Example IC50 ( ⁇ M) 1 1.156 1.01 0.293 1.02 0.444 1.03 0.007 1.04 0.008 1.05 0.004 1.06 0.255 1.07 6.108 1.08 1.1995 1.09 0.118 1.10 0.002 1.11 0.001 1.12 0.44 1.13 0.001 1.14 0.064 1.15 0.0585 1.16 0.001 1.17 0.025 1.18 0.013 1.19 0.004 1.20 0.019 1.21 0.118 1.22 0.007 1.23 0.004 1.24 0.012 1.25 0.002 1.26 0.01 2 0.342 2.01 1.5 3 0.031 4 0.573 5 1.3445 6 0.6225 7 0.0145 7.01 0.001 7.02 0.003 7.03 0.004 8 0.0085 8.01 0.0075 8.02 0.014 8.03 0.0055 8.04 0.1665 8.05 0.093 8.06 0.003 8.07 0.001 8.08 0.0015 8.09 0.001 9A 0.004 9B 0.005
• the compounds of formula (I) and their pharmaceutically acceptable salts can be used as medicaments (e.g. in the form of pharmaceutical preparations).
• the pharmaceutical preparations can be administered internally, such as orally (e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories).
• the administration can also be effected parenterally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).
• the compounds of formula (I) and their pharmaceutically acceptable salts can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragées and hard gelatin capsules.
• Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragées and hard gelatin capsules.
• Suitable adjuvants for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.
• Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.
• Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.
• Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.
• the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
• the dosage can vary in wide limits and will, of course, be fitted to the individual requirements in each particular case.
• the pure enantiomers can be obtained by methods described herein or by methods known to those skilled in the art, such as e.g. chiral chromatography or crystallization.
• Acetyl chloride (8.7 mg, 110 ⁇ mol) was added at 0° C. to a suspension of (3aR,6aS)-3,5-dichlorobenzyl 5-(4-aminobenzoyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (example 1.06; 40 mg, 92.1 ⁇ mol) and triethylamine (28.0 mg, 276 ⁇ mol) in dichloromethane (1 mL). The ice bath was removed, then after 90 min another portion of acetyl chloride (5.8 mg, 73 ⁇ mol) was added, then after another 2 h the reaction mixture was partitioned between dichloromethane and brine.
• Step 1 (3aR,6aS)-3,5-Dichlorobenzyl 5-(5-(N-(methylsulfonyl)methylsulfonamido)-picolinoyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate
• Step 2 (3aR,6aS)-3,5-Dichlorobenzyl 5-(5-(methylsulfonamido)picolinoyl)hexahydro-pyrrolo[3,4-c]pyrrole-2(1H)-carboxylate
• Step 1 (3aR,6aS)-2-tert-Butyl 5-(3,5-dichlorobenzyl)tetrahydropyrrolo[3,4-c]pyrrole-2,5(1H,3H)-dicarboxylate
• Step 2 (3aR,6aS)-3,5-Dichlorobenzyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate hydrochloride
• Step 1 (3aR,8aS)-tert-butyl 6-((E)-3-(4-(trifluoromethoxy)phenyl)acryloyl)octahydro-pyrrolo[3,4-d]azepine-(1H)-carboxylate
• Step 2 (E)-1-((3aR,8aS)-Octahydropyrrolo[3,4-d]azepin-6(7H)-yl)-3-(4-(trifluoromethoxy)-phenyl)prop-2-en-1-one hydrochloride
• Step 1 (3aS,6aS)-tert-Butyl 5-(4-sulfamoylbenzoyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate
• Step 2 4-((3aR,6aR)-Octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzenesulfonamide hydrochloride (intermediate 4)

Priority Applications (1)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=47843184

Family Applications (2)

Family Applications After (1)

Country Status (33)

Cited By (18)

Families Citing this family (17)

Family Cites Families (138)

• 2014
  • 2014-03-10 AR ARP140100780A patent/AR095079A1/es unknown
  • 2014-03-11 TW TW103108493A patent/TWI678368B/zh not_active IP Right Cessation
  • 2014-03-11 KR KR1020157027949A patent/KR20150126036A/ko active IP Right Grant
  • 2014-03-11 PT PT147088918T patent/PT2970256T/pt unknown
  • 2014-03-11 ES ES14708891T patent/ES2763417T3/es active Active
  • 2014-03-11 EA EA201591497A patent/EA035015B1/ru not_active IP Right Cessation
  • 2014-03-11 LT LTEP14708891.8T patent/LT2970256T/lt unknown
  • 2014-03-11 PE PE2015001912A patent/PE20151605A1/es active IP Right Grant
  • 2014-03-11 AU AU2014230943A patent/AU2014230943B8/en not_active Ceased
  • 2014-03-11 MY MYPI2015703023A patent/MY177574A/en unknown
  • 2014-03-11 SI SI201431438T patent/SI2970256T1/sl unknown
  • 2014-03-11 DK DK14708891.8T patent/DK2970256T3/da active
  • 2014-03-11 SG SG11201507396YA patent/SG11201507396YA/en unknown
  • 2014-03-11 WO PCT/EP2014/054631 patent/WO2014139978A1/en active Application Filing
  • 2014-03-11 RS RS20191633A patent/RS59682B1/sr unknown
  • 2014-03-11 HU HUE14708891A patent/HUE046776T2/hu unknown
  • 2014-03-11 MA MA38432A patent/MA38432B1/fr unknown
  • 2014-03-11 PL PL14708891T patent/PL2970256T3/pl unknown
  • 2014-03-11 MX MX2015011311A patent/MX2015011311A/es active IP Right Grant
  • 2014-03-11 CN CN201480013590.XA patent/CN105073748B/zh active Active
  • 2014-03-11 UA UAA201509650A patent/UA115354C2/uk unknown
  • 2014-03-11 EP EP14708891.8A patent/EP2970256B1/en active Active
  • 2014-03-11 CA CA2901047A patent/CA2901047A1/en not_active Abandoned
  • 2014-03-11 BR BR112015022804A patent/BR112015022804A2/pt active Search and Examination
  • 2014-03-11 JP JP2015562081A patent/JP6483034B2/ja active Active
• 2015
  • 2015-08-18 ZA ZA2015/05944A patent/ZA201505944B/en unknown
  • 2015-08-24 IL IL240796A patent/IL240796B/en active IP Right Grant
  • 2015-08-24 CR CR20150436A patent/CR20150436A/es unknown
  • 2015-08-26 CL CL2015002386A patent/CL2015002386A1/es unknown
  • 2015-09-02 PH PH12015501934A patent/PH12015501934B1/en unknown
  • 2015-09-10 US US14/850,497 patent/US20150376194A1/en not_active Abandoned
  • 2015-12-30 HK HK15112840.0A patent/HK1211935A1/xx unknown
• 2018
  • 2018-05-09 US US15/975,528 patent/US10913745B2/en active Active
• 2019
  • 2019-02-13 JP JP2019023259A patent/JP2019089828A/ja active Pending
  • 2019-12-17 HR HRP20192274TT patent/HRP20192274T1/hr unknown

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events